top of page
Pharma & Healthcare Investment
Covers pharmaceuticals, biotech, medical devices, diagnostics, healthcare systems, and increasingly AI applied to drug discovery and healthcare. Drug development is long, complex, and science-driven. Understanding the biology, chemistry, and clinical pipeline behind a company tells you more than its balance sheet. This category analyzes pharmaceutical and biotech opportunities through a science-first lens — from molecule to market — so you can read the opportunity before the stock price moves.
Pharma vs. Medtech ETFs: What You're Actually Buying
The medtech ETF beat the pharma ETF over the last decade — not because medtech won, but because two stocks inside it did. Here's what you're actually buying, and why the S&P 500 beat both anyway.
2 days ago
1,451 AI Medical Devices, Two Real Winners: The Truth About AI in Medtech
The FDA has cleared 1,451 AI medical devices since 1995. Only two have ever proven they actually change what happens to a patient — everything else has proven it's accurate, not that it matters.
3 days ago
The Medtech Moat AI Can't Easily Break
AI is changing medical technology in two opposite ways. Using Abbott's cardiovascular devices and Intuitive Surgical's robotic platform as case studies, this article shows how AI strengthens the core switching-cost moat while gradually eroding the vendor-specific software layer surrounding it.
3 days ago
AI Won't Save Medtech From Pharma — It Might Make the Gap Worse
Artificial intelligence is transforming both pharma and medtech—but not in the same way. This article explains why AI reinforces pharma's patent-based competitive advantage while offering only limited moat expansion for most medical device companies, and what that means for long-term investors.
3 days ago
The Medtech Moat Map: Where the Advantage Is Real
Most medtech companies compete on execution rather than durable competitive advantage. This article introduces a practical framework for evaluating medical-device moats by separating moat strength, moat mechanism, and publicly verifiable evidence. Learn why switching costs—not patents—drive the strongest competitive advantages in surgical robotics, cardiovascular devices, orthopedic implants, and cochlear implants.
3 days ago
The Full Stack of a Pharma Bet: From Molecule to Dollar
Casgevy's climb from $10 million to a projected half-billion in revenue looks like one decision. It's actually six — and the same stack explains almost any pharma company's next move.
6 days ago
The Acquirer's Playbook: How a Pharma VP Actually Chooses What to Buy
What actually happens inside a pharma company before a $10 billion acquisition gets announced? This piece maps the real decision framework — build vs. partner vs. buy, the screening checklist, and why a target's leverage is easy to underestimate — using real negotiations like Novartis's standoff with Avidity Biosciences.
7 days ago
Pharma's De-Risking Playbook: How Big Pharma Really Chooses What to Buy
A $300 billion patent cliff is reshaping how Big Pharma buys. This piece maps five years of deal data to show why two-thirds of acquisitions are still bets on unproven science, how J&J's incubator network actually pays off, and what separates a slow "partner-first" deal like Roche/Genentech from a cold, competitive bidding war like GSK/Nuvalent.
7 days ago
The Target's Playbook: How a Startup Actually Gets Acquired by Big Pharma
Getting acquired well isn't luck — it's the result of decisions made years earlier. Using SEC filings from Seagen, Avidity Biosciences, and Verona Pharma, this piece walks through exactly how founders identify the right buyer, price their asset, and negotiate from strength instead of desperation.
Jul 14
AI Can Out-Invent Big Pharma. It Still Can't Out-Build It.
AI in pharma is often described as one trend. It's really two, and it only wins one on its own merits. In drug discovery, AI directly attacks the problem of finding the right molecule, letting small teams compete with giants using nothing but data and talent. In drug manufacturing, AI can't shortcut anything, since it depends on years of proprietary production data that only exists once a company has already built an expensive facility, for reasons that have nothing to do wit
Jul 10
bottom of page